FOSUN PHARMA's HLX07 Combined with Serplulimab Injection and Chemotherapy Cleared for Clinical Trial in Advanced Squamous Non-Small Cell Lung Cancer

Stock News03-16

FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries recently received approval from the National Medical Products Administration to conduct a clinical trial for HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) combined with Serplulimab injection and chemotherapy as a treatment for advanced squamous non-small cell lung cancer (sqNSCLC). Henlius plans to carry out related clinical studies in China once conditions are met. As of the announcement date, there are no similar combination therapy regimens approved globally. By February 2025, the cumulative R&D investment in this treatment regimen by the group amounted to approximately RMB 93 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188326337?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188326337","market":"nz","top_or_hot":-1,"title":"FOSUN PHARMA's HLX07 Combined with Serplulimab Injection and Chemotherapy Cleared for Clinical Trial in Advanced Squamous Non-Small Cell Lung Cancer","media":"Stock News","content":"<p>FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries recently received approval from the National Medical Products Administration to conduct a clinical trial for HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) combined with Serplulimab injection and chemotherapy as a treatment for advanced squamous non-small cell lung cancer (sqNSCLC). Henlius plans to carry out related clinical studies in China once conditions are met. As of the announcement date, there are no similar combination therapy regimens approved globally. By February 2025, the cumulative R&D investment in this treatment regimen by the group amounted to approximately RMB 93 million.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA's HLX07 Combined with Serplulimab Injection and Chemotherapy Cleared for Clinical Trial in Advanced Squamous Non-Small Cell Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA's HLX07 Combined with Serplulimab Injection and Chemotherapy Cleared for Clinical Trial in Advanced Squamous Non-Small Cell Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-16 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries recently received approval from the National Medical Products Administration to conduct a clinical trial for HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) combined with Serplulimab injection and chemotherapy as a treatment for advanced squamous non-small cell lung cancer (sqNSCLC). Henlius plans to carry out related clinical studies in China once conditions are met. As of the announcement date, there are no similar combination therapy regimens approved globally. By February 2025, the cumulative R&D investment in this treatment regimen by the group amounted to approximately RMB 93 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1188326337","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188326337","pubTimestamp":1773658232,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries recently received approval from the National Medical Products Administration to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0187":"一线龙头","BK1191":"制药","02196":"复星医药","BK0096":"民营医院","BK1515":"抗疫概念","BK1593":"医美概念股","BK0012":"证金概念","BK0188":"融资融券","BK0175":"白马股","BK0196":"行业龙头","BK0060":"抗癌"},"translate_title":"复星医药HLX07联合斯鲁利单抗注射液和化疗治疗晚期鳞状非小细胞肺癌获批临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries recently received approval from the National Medical Products Administration to conduct a clinical trial for HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) combined with Serplulimab injection and chemotherapy as a treatment for advanced squamous non-small cell lung cancer (sqNSCLC). Henlius plans to carry out related clinical studies in China once conditions are met. As of the announcement date, there are no similar combination therapy regimens approved globally. By February 2025, the cumulative R&D investment in this treatment regimen by the group amounted to approximately RMB 93 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188326337","isCrawlerRequest":true}